[Axicabtagene ciloleucel (diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V (expiry of the decision)]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004142
Original Title: Axicabtagen-Ciloleucel (diffuses großzelliges B-Zell-Lymphom und primaer mediastinales großzelliges B-Zell-Lymphom) - Bewertung gemäß § 35a Abs. 1 Satz 11 SGB V (Ablauf Befristung)
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, B-Cell
  • Biological Products
  • Antineoplastic Agents, Immunological
  • Immunotherapy, Adoptive
  • Receptors, Chimeric Antigen
  • Axicabtagene Ciloleucel
  • Lymphoma - Large B-Cell - Diffuse
  • Lymphoma - B-Cell
  • Health Care Costs
  • Epidemiology
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.